SALT LAKE CITY, Nov. 11, 2019 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug…Original Article
Lipocine Receives Complete Response Letter for TLANDO™ from U.S. FDA
